Excerpts

In subprofile C1, a negative trend was observed in COPD patients, largely due to an increase in sPAP, particularly by the third year of follow-up.

et al.) [ 18 ] showed a trend in DBP reduction (−4.20 mmHg), while the other two studies (Husain M. et al. and Volpe S. et al.) [ 16 , 19 ] did not demonstrate statistically significant changes in DBP.

PIV and NLR showed a trend toward increased risk but did not reach statistical significance.

PLR ≥ 120.5 demonstrated borderline significance.

The only nominally significant shift in the control group was a decrease in β-NGF, but given the limited number of measurable β-NGF samples and their variability, this apparent change was not deemed meaningful.

Although relatively rare, the incidence of combined SCLC has shown an increasing trend.

In patients without T2DM, testosterone inversely correlated with NT-proBNP, showed no significant correlation with LVDD or the NYHA class, and showed a borderline significance with the duration of HF ( Table 3 ).

The participants showed a trend in the loss of total body mass, fat percentage and fat mass 6–7 years before diagnosis, reaching significance 3–5 years into disease progression [ 21 ].

Among these, LAScd ( p = 0.019) and SBP ( p = 0.083) remained significant or near-significant after correction, confirming limited overfitting and good internal consistency of the final model ( Supplementary Materials Table S1 ).

Reflecting this dynamic, the OSDI in our study showed a more pronounced postoperative improvement compared to the DEQ-5, which reached only borderline significance.

In terms of visual outcomes, BCVA did not change after one or two injections, but showed a trend toward decline after the third injection.

It was also linked to greater “ motor delay ” (r = −0.207, p = 0.016), and there was a clear trend toward more severe “ cognitive delays ” (data upon request).

While sex- and age-related differences were modest, associations with DAL severity were highly significant ( Supplementary Table S1 ).

In the Henderson model, ΔHCO 3 is strongly positive and ΔPCO 2 strongly negative—both highly significant—consistent with the Henderson–Hasselbalch framework.

All of these correlations were highly significant, with a p -value of <0.001. 4.

Phyac and Fitscore versus Caloric intake: In Table 2 , the mean levels of Calorie intake regularly increase from Class 1 to Class 3 of the two indexes, and in both cases, the ANOVA across the three classes is highly significant for heterogeneity and trend.

These results are partly consistent with a previous preliminary analysis [ 21 ] from our group, where it was observed that the mean PBVC/y was lower in MOGAD patients than in RRMS patients in a subgroup of patients aged <60 years and with a disease duration of ≤10 years, with borderline significance.

In our study, the difference was marginally significant; it may be one of the reasons that more LNs were harvested in the proximal type (distal type vs. caudal type vs. proximal type: 6 (0–19) vs. 5 (0–16) vs. 7 (0–20); p = 0.0879).

No significant differences or marginally significant expressions were observed between individual genes or gene sets from epithelial brushings and bronchial biopsies when comparing severe and non-severe asthma cases.

Interestingly, external/internal rotation during the “wash” and “apron” tasks exceeded normative values postoperatively, while abduction during the “book” task showed a trend towards improvement compared to controls.

Other markers, including CRP, PCT, IgG, and albumin, were not significantly associated with mortality; however, platelets and qSOFA exhibited borderline significance.

In group N, PSP similarly showed negative trends with ANC and IgG and a positive trend with albumin, though again without reaching significance.

Length of stay was a highly significant predictor, where each additional day increased the odds of transfusion by 16% (OR = 1.16, 95% CI: 1.14–1.17) and the rate of units by 15% (IRR = 1.15, 95% CI: 1.13–1.17).

However, a large observational study from Japan (n = 1032) showed borderline significant results for MACE compared to bisphosphonates (weighted 3-year RR 1.36 [95% CI, 0.99–1.87], weighted 3-year RD 8.2% [95% CI, −0.2% to 16.7%]) that need to be confirmed [ 135 ].

(seven placebo-controlled trials, n = 7428, follow-up 12 months) was marginally non-significant with a HR of overall fracture risk reduction with ibandronate vs. placebo of 0.78 (95% CI, 0.746–1.018) [ 87 ].